MAPT and Alzheimer disease: However, despite early optimism from active and passive immunization trials targeting Aβ and Tau, these approaches have thus far failed to slow disease progression in AD patients and even in MCI subjects significantly6–15, likely because the treatment was initiated too late16,17.